Nihad Hasagic

Clinigen has appointed Nihad Hasagic as SVP for CLS

Clinigen has appointed Nihad Hasagic as Senior Vice President for Clinigen Lifecycle Services (SVP CLS).

CLS plays a key role in Clinigen’s growing service portfolio, helping to facilitate accelerated pathways to patients for critical medicines at every stage of their life cycle, even in complex markets.

This key appointment is part of a broader leadership realignment designed to sharpen the company’s focus on achieving its growth objectives and capitalise on key market opportunities.

Previously, as SVP of strategic initiatives, Nihad was pivotal in successful acquisitions and the development of the company’s core growth strategy, including his foundational work in launching CLS and shaping its commercial strategy.

This track record, combined with over 20 years of experience in the healthcare, life science and specialty chemicals industries – leading multiple acquisitions and corporate initiatives – makes him exceptionally well-suited to lead the new division and capture opportunities in the rapidly expanding specialist pharma services market.

Jerome Charton, CEO of Clinigen, says: “There is no one better placed than Nihad to lead Clinigen Lifecycle Services as we continue to strengthen our market presence, capture high-growth specialist pharma services opportunities, and drive enhanced returns for our investors.”

Nihad Hasagic enthused: “I’m excited to focus on accelerating the growth of CLS by strengthening our industry position and ensuring we continue to deliver value to our clients and stakeholders.

“With the foundation we’ve already built, we can better support the transition of innovative medicines and have a positive impact on patients’ lives.”